Hengrui Medicine (600276.SH): Injection SHR-A2102 obtained a drug clinical trial approval letter.

Financial and Economic News APP reported that Hengrui Medicine (600276.SH) announced that recently, its subsidiaries, Suzhou Shengdiya Biomedical Pharmaceutical Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd., received the approval notice for clinical trial of injection SHR-A2102 issued by the National Medical Products Administration. The clinical trial will be conducted soon.